Teva U.S. sales plummet, Copaxone sets record

Generics giant Teva Pharmaceutical Industries ($TEVA) suffered another decline in U.S. sales, dampening third-quarter results. The Israeli company saw net income drop by 12.8% to $916 million, with U.S. revenues dropping by a whopping 48% to $845 million, compared with a period last year marked by several new product launches. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.